ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-CD22-antibody-drug-conjugate
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-CD22-antibody-drug-conjugate
3
trial(s) found.
NCT07123454
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (
Lumi-NHL
)
anti-CD22 antibody-drug conjugate
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT07109219
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia (
ALLight
)
anti-CD22 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
VIC (3)
NSW (2)
NZ (1)
QLD (1)
SA (1)
TAS (1)
WA (1)
Phase
Phase 1 / Phase 2 (2)
Phase 3 (1)
Trial Type
Haem (2)
Paed (1)
Cancer Therapy Class
CD22
100%
CD19
33%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6009 - Perth - Perth Children's Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Lymphoid leukaemia
Lymphoma
Non-Hodgkin's lymphoma
Mixed phenotype acute leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy